Trials / Withdrawn
WithdrawnNCT05252520
A Study of JNJ-77474462 (Bermekimab) in Healthy Chinese Participants
A Phase 1 Open-label Single Ascending Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of JNJ-77474462 (Bermekimab) in Healthy Chinese Participants Following Subcutaneous Administration
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the pharmacokinetics (PK) of JNJ-77474462 following single ascending dose subcutaneous (SC) administration to healthy Chinese participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-77474462 | JNJ-77474462 will be administered subcutaneously. |
Timeline
- Start date
- 2023-05-01
- Primary completion
- 2023-11-20
- Completion
- 2023-11-20
- First posted
- 2022-02-23
- Last updated
- 2025-02-03
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05252520. Inclusion in this directory is not an endorsement.